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Abstract
The objective of this study was to evaluate how much limb fat is needed to be lost for lipoatrophy to become
clinically evident. Antiretroviral drug-naive patients from a randomized trial comparing stavudine or abacavir
plus lamivudine and efavirenz, who had subjective assessment to detect clinically evident lipoatrophy (stan-
dardized questionnaire) and objectivemeasurements of limb fat (dual X-ray absorptiometry) at baseline, 48weeks,
and 96 weeks were included. ROC curves were used to assess the sensitivity and specificity of several cut-off
values of absolute and percent limb fat loss for diagnosing lipoatrophy. Of 54 patients included, 13 (24%) had
subjective lipoatrophy at 96 weeks. After 96 weeks, median limb fat change was2.3 kg (interquartile range:5.2,
þ0.2) and 0.4 kg (interquartile range: 7.2, þ3.4) in patients with and without lipoatrophy, respectively. Median
percent limb fat changewas45.5% (interquartile range:78.0,þ3.7) and 5.5% (interquartile range:62.8,þ95.6),
respectively. The cut-off values of absolute and percent limb fat loss showing the best sensitivity and specificity
values were 1.5 kg (sensitivity, 77%; specificity, 76%) and 30% (sensitivity, 85%; specificity, 73%). At least 30%
limb fat is needed to be lost in HIV-infected patients for lipoatrophy to become clinically evident.
Introduction
Long-term toxicity such as metabolic disturbances andbody fat changes remains an important limitation of
highly active antiretroviral therapy (HAART).1–3 The latter,
known as lipodystrophy, is a complex feature, whose patho-
genesis is not completely understood.1 It is a stigmatizing
condition that leads to psychological and social problems,
makes adherence to therapy difficult, and is sometimes as-
sociated with metabolic alterations. Lipodystrophy may
present as central fat increase, known as lipohypertrophy,
peripheral (face, limbs, and buttocks) fat loss, termed lipoa-
trophy, or both manifestations.1,2 Among other factors, such
as the effect of HIV infection itself,4 protease inhibitors have
been cited as participating in the development of lipohyper-
trophy, whereas thymidine analogs, through a mechanism of
mitochondrial toxicity, seem to play an important role in
lipoatrophy.3,5
Lipodystrophy is usually defined clinically. Although the
subjective definition may be easy to use in the clinical setting,
it is less useful for clinical research. Several methods, such as
dual energy X-ray absorptiometry (DEXA), anthropometric
measures, computed tomography scanning, and others,6,7 can
assess body fat objectively, but they do not directly provide
the diagnosis of lipodystrophy. Although several attempts
have been made to develop an objective definition, there is no
clear operative definition for lipodystrophy.6–8
In two randomized clinical trials, fat changes were assessed
using an arbitrary criterion of 20% peripheral fat loss mea-
sured by DEXA to define lipoatrophy.9,10 In these studies,
efavirenz combined with two nucleosides was found to be
associated with a greater incidence of this so-defined lipoa-
trophy when compared with lopinavir combined or not with
two nucleosides.9,10 To understand the clinical relevance of
these findings, it is important to know the relationship be-
tween a20%peripheral fat loss and the diagnosis of clinically
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evident lipoatrophy. Thus, the objective of this study was to
evaluate how much limb fat is needed to be lost for lipoa-
trophy to become clinically evident in a subset of antiretroviral
drug-naive HIV-infected patients from a randomized clinical
trial who had subjective assessment of lipoatrophy and ob-
jective measurements of limb fat.
Patients and Methods
The ABCDE study was a 96-week randomized clinical trial
evaluating as primary end point the incidence of lipoatrophy
in 237 HIV-infected naive patients initiating lamivudine=
efavirenz plus stavudine or abacavir.11 Lipoatrophy was as-
sessed by a predefined questionnaire modified from previous
publications,12 performed at 48 and 96 weeks. Anthropo-
metric measurements performed at the same time points ac-
cording to standard techniques are described elsewhere.13
Lipoatrophy features included decreased subcutaneous fat
tissue in the face, buttocks, and=or extremities. The morpho-
logical abnormality at the precise site was diagnosed when
reported by the patient and confirmed by medical examina-
tion.11 In addition, after giving their informed consent, pa-
tients from six participating centers located near the DEXA
center (Centro Te´cnico de Iso´topos Radioactivos, CETIR,
Barcelona, Spain) underwent DEXA scanning (Lunar DPX-L
Equipment, Madison, WI) at baseline and at 48 and 96 weeks.
Clinical assessment and DEXA were performed by different
investigators blinded to the results of the other evaluation.
Data from patients with DEXA scan and clinical evaluation
were analyzed for the present study.
Descriptive statistics of baseline characteristics were cal-
culated overall and for each group according to clinically
diagnosed lipoatrophy. A comparison of limb fat loss was
performed between groups established according to their
baseline total fat evaluated by DEXA or baseline weight (pa-
tients distributed into two groups, those above and below the
median values of total fat and weight). Receiver operating
characteristic (ROC) analysis was used to assess the sensitiv-
ity and specificity of absolute and percent limb fat loss as
diagnostic criteria for defining lipoatrophy. Sensitivity and
specificity were calculated for every 0.5 kg of absolute limb fat
loss and every 5% of percent limb fat loss.
Results
In the ABCDE study, a lower proportion of patients as-
signed to abacavir developed clinical signs of lipoatrophy
(4.8% vs. 38.3%; p< 0.001).
Fifty-four patients had a clinical evaluation and DEXA scan
performed at the three time points: 13 (24%) were clinically
diagnosed with lipoatrophy (LA) and 41 (76%) were not
(no-LA). As mentioned in the original publication of the
ABCDE study,11 within this subgroup of patients, both arms
presented baseline characteristics similar to those of the total
study population except for serum cholesterol concentration
(data not shown). The groups were well balanced for baseline
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FIG. 1. Sensitivity and specificity of three different proportions of limb fat loss on DEXA (20%, 30%, and 35%) for the
diagnosis of clinically evident lipoatrophy (LA).
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characteristics, with 77.8% men and 88.9% white. HIV risk
groups were distributed as follows: 11.1% former drug users,
33.3% homosexuals, 46.3% heterosexuals, and 9.3% others.
Among the total, 16.7% had prior AIDS, median CD4 was 196
cells=ml, andmedian viral load was 99,265 copies=ml. Patients
received lamivudine=efavirenz plus stavudine in 53.7%, and
lamivudine=efavirenz plus abacavir in 46.3%. Median weight
was 65 kg, andmedian limb fat on DEXAwas 5.7 kg. The only
variable showing a significant difference between groups was
age: median of 39 years in the no-LA group and 50 years in the
LA group ( p¼ 0.036).
After 48 weeks, median absolute limb fat was 5.8 kg (range
4.2; 7.6) in the no-LA group and 3.9 kg (3.1; 5.1) in the LA
group ( p¼ 0.073), median limb fat loss was0.2 kg (6.0; 3.4)
in no-LA and 1.9 kg (3.9; 3.8) in LA ( p¼ 0.199), and
median percent limb fat change was 2.4% (63.8; 107.6) in
no-LA and 34.7% (77.3; 89.1) in LA ( p¼ 0.108). After 96
weeks, the median absolute limb fat was 6.2 kg (3.0; 8.1) in
no-LA and 3.0 kg (1.6; 4.0) in LA ( p¼ 0.002), median limb fat
loss was 0.4 kg (7.2; 3.4) in no-LA and 2.3 kg (5.2; 0.2) in
LA ( p¼ 0.002), and median percent limb fat change was 5.5%
(62.8; 95.6) in no-LA and 45.5% (78.1; 3.7) in LA
( p< 0.001).
The proportion of limb fat loss was independent of total fat
assessed by DEXA at baseline (15kg [median baseline total
fat of the 54 patients] vs.15kg). In patientswith baseline total
fat 15kg, the percent limb fat change at 96 weeks was 7.5%
(49.3; 95.6) in the no-LA group and42.9% (78.1; 3.7) in the
LA group ( p¼ 0.019), whereas in patients with baseline total
fat>15kg the percent limb fat changewas 3.8% (62.8; 40.9) in
no-LA and48.4% (57.9;32.8) in LA ( p¼ 0.006). Similarly,
the proportion of limb fat loss was independent of baseline
weight (965 kg [median baseline weight of the 54 patients]
vs. >65kg). In patients with a baseline weight 965 kg, the
percent limb fat change at 96 weeks was 0.6% (49.3; 95.6) in
the no-LA group and 47.0% (78.1; 3.7) in the LA group
( p¼ 0.006), and in patients with baseline weight >65kg, the
percent limb fat change was 7.5% (62.8; 91.5) in no-LA and
40.0% (57.9; 15.2) in LA ( p¼ 0.040).
The sensitivity and specificity of three different percentages
of limb fat loss evaluated by DEXA (20%, 30%, and 35%) for
diagnosing clinically evident LA are shown in Fig. 1. ROC
curves showing the sensitivity and specificity of absolute
and percent limb fat changes for diagnosing clinically evident
LA are presented in Fig. 2. Thirty percent was the best cut-off
for percent limb fat loss (sensitivity, 85%; specificity, 73%),
whereas 1.5 kg was the best cut-off in terms of absolute
changes in limb fat loss (sensitivity, 77%; specificity, 76%)
(sensitivity and specificity for other cut-offs are not shown).
Discussion
To our knowledge, this is the first study that attempts in a
prospective way to correlate the percentage of peripheral fat
loss evaluated by DEXA scanning with the presence of clini-
cally evident LA.
If the 20% fat loss cut-off used to define LA in the
ACTG5142 and M03-613 studies9,10 had been used in our
study, more than one-third (36.6%; Fig. 1) of patients without
clinically evident LA would have been ‘‘erroneously’’ diag-
nosed as having LA. On the other hand, if the cut-off had been
35%, a reduction in false-positive LA to 24.4% would occur,
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FIG. 2. ROC curves show the sensitivity and specificity of absolute and percent limb fat changes for diagnosing clinically
evident lipoatrophy.
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but sensitivity (patients with a clinical diagnosis of LA iden-
tified as LA) would decrease from 84.6% to 69.2%. Thus,
based on the ROC curves, 30%was the best cut-off in terms of
sensitivity and specificity for the diagnosis of clinically evi-
dent LA. However, we should recognize that, approximately
one-quarter of patients without clinical lipoatrophy would be
diagnosed of lipoatrophy using this 30% cut-off.
These data are in agreement with an analysis of data from
ACTG 5142, in which investigators realized that most patients
with 20% peripheral fat loss did not present evident lipoa-
trophy.14
These findings do not try to minimize the potential rele-
vance of losing 20% of limb fat, but it should be noted that this
amount of fat loss is not evident to the observer in most cases.
Actually, median limb fat loss in our patients was 45%, far
from the 20% used to define lipoatrophy in the aforemen-
tioned clinical trials. Another consideration is that a loss of
20% of peripheral fat may herald an increasing loss in the next
months or years. This possibility should be examined in large
prospective surveys that include clinical evaluation and
DEXA scanning. If this is confirmed, we hypothesize that the
preclinical finding of 20% or less fat loss might be a useful
signal to switch antiretroviral regimens to prevent the de-
velopment of clinically evident lipoatrophy; that is, to act
before crossing the 20% line.
Although thymidine analogs, the nucleoside analogs
most often related with lipoatrophy, have been relegated as
alternative treatment options for antiretroviral drug-naive
patients,15 the long-term probability of developing this com-
plication with use of the less toxic nonthymidine analogs
is unknown. In addition, a role of other antiretroviral com-
pounds in lipoatrophy through different mechanisms cannot
be ruled out.16
This study has the limitation of a small sample size; thus,
our findings should be taken with caution and confirmed in
larger series. In addition, although we have observed that
the high percentage of peripheral fat loss is independent of
baseline total fat or weight, we do not knowwhether our data
apply similarly to individuals of both sexes, or to different age
groups or races.
In conclusion, >20% peripheral fat loss is not clinically
evident in most patients. Hence, and despite its limitations,
>30% might be a better cut-off to objectively define lipoa-
trophy in HIV-infected patients under antiretroviral therapy.
If this cut-off value is confirmed in further studies, it could be
of use for clinical care and research purposes.
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